Encyclopedia entry
Tesamorelin
Tesamorelin is a growth-hormone-releasing-hormone (GHRH) analogue. Unique on this list because it is the only peptide we cover that holds an FDA-approved marketing authorisation. EGRIFTA and EGRIFTA WR (Theratechnologies) are licensed in the US for HIV-associated lipodystrophy. There is no UK or EMA marketing authorisation. The NHS does not prescribe tesamorelin for any indication. UK availability is via research-peptide retailers only.
Pharmaceutical history
- · Developed by Theratechnologies (Canada).
- · FDA approved as EGRIFTA in 2010 for HIV-associated lipodystrophy.
- · Reformulated as EGRIFTA WR in 2023 for improved stability.
- · Phase III data on visceral adipose tissue reduction supported the original approval.
- · Off-label discussion in longevity and biohacker communities focuses on visceral fat reduction in non-HIV populations. There is no UK-licensed pathway for this off-label use.
UK regulatory status
- · No UK marketing authorisation. NHS does not prescribe.
- · Not controlled under the Misuse of Drugs Act 1971.
- · Sold by UK research-peptide retailers under "research use only" framing.
- · On the WADA prohibited list (S2 peptide hormones class).
Why this entry exists
Tesamorelin sits in a different regulatory zone than the other peptides on this list because it has an FDA-approved indication. That does not make UK off-label use sanctioned. Anyone wanting tesamorelin for a non-HIV indication in the UK is in research-chemical territory, with no clinical supervision and no UK licensing route. The encyclopedia entry is here so readers understand the regulatory geography rather than assume FDA approval translates directly to UK availability.
UK retailer comparison: research peptides UK retailers.
Popular on PeptideClear
Ready to buy
Buy TESAMORELIN in the UK
UK retailers compared by price, Trust Index, and CoA practice. Editorial commentary only. Research use only.